Johns Hopkins Immunotherapy Paper: 100% CRC cure rate in a poorly immunogenic CRC Mouse Model

[Sleen]

Much appreciated!

Celine

[ieowi]

I Got the paper, interested ? Dm ur email

[dianetavegia]

DK, have you heard any updates on CD47? The human trials were to start around June 2014. I last wrote them in March 2014 and they were to begin with one patient then add more LOCAL patients to watch for safety, etc.

3/3/2014

Hi,

We are proceeding as planned for the start of the phase I trial before mid-year, but we don’t yet have any information about exclusion and inclusion criteria. The first trial will be a small safety trial, starting with one patient and adding patients if all is successful as the months go by.

I imagine that in the future, if the initial trials are successful, a trial might be done using the antibody to prevent recurrence, but at this point all plans are focused on the initial trials.



Christopher Vaughan
Communications Officer
Stanford Institute for Stem Cell Biology and Regenerative Medicine
265 Campus Drive G3C104
Stanford, CA 94305
(650) 736-8849
vaughan1@stanford.edu

The CIRM-funded team at Stanford began an early phase trial in August 2014 using an antibody that blocks a receptor on the surface of CSCs called CD47. One of the researchers on the team, Irving Weissman, has dubbed that gene the “don’t eat me gene(video)” because it tells the immune system cells responsible for getting rid of tumors to not do their job. When CD47 is blocked, the immune system cells called macrophages are able to destroy—in essence eat—the CSCs.

The initial study primarily seeks to determine safety and the best dose for moving forward. It is enrolling patients with advanced-stage solid tumors. So far 12 patients have been treated with five different doses, and the team continues to screen patients for higher doses to be treated in the coming months. The trial is open only at Stanford Cancer Center under the leadership of Branimir Sikic.

The team at ImmunoCellular plans to enroll 400 brain cancer patients at 120 clinical trial sites around the U.S., Canada and Europe. They are also developing a way to turn a patient’s dendritic cells into a vaccine that helps the immune system target cancer stem cells.


The anti-CD47 cancer therapy clinical trials

The clinical trials of the anti-CD47 antibody are underway. As with most FDA phase-1 safety trials, the clinical trial is small and is not currently recruiting additional patients.

If and when the clinical trial has openings for additional participants, an announcement will be made on this page. In the meantime, patients can search for currently open trials in the United States through the NIH Clinical Trials Database. Other clinical trials at Stanford can be found here.

http://stemcell.stanford.edu/CD47/

[jortego128]

Interesting about the cancer vaccine. Reminds me of the Etubics company we talked about earlier that claims to have some very promising combination tests with their already very effective (so they say) new vaccine with at least two more drugs from NCI.

DK, this is great news, lets just keep fingers crossed they start some clinical trials sooner rather than later!

[DK37]

DK, have you heard any updates on CD47? The human trials were to start around June 2014.

http://stemcell.stanford.edu/CD47/

Hi Dianetavegia,

There was a lot of excitement on CD47 as a target when its preclinical publication came out. I have not heard anything (good or bad) about the Stanford trial.
Of note: Celgene has an anti-CD47 clinical trial as well with multiple locations, their drug is called "CC-90002"
Here is the Celgene trial's link:
https://clinicaltrials.gov/ct2/show/NCT ... d47&rank=1

-DK

[DK37]

Interesting about the cancer vaccine. Reminds me of the Etubics company we talked about earlier that claims to have some very promising combination tests with their already very effective (so they say) new vaccine with at least two more drugs from NCI.

DK, this is great news, lets just keep fingers crossed they start some clinical trials sooner rather than later!

My personal opinion is that although therapeutic cancer vaccines have struggled over the years, they have some definite potential when combined with the new immunotherapy drugs. I think too often in the past, it was somewhat futile for these vaccines to try to "train the immune system" when tumors often do such a good job of suppressing the immune response - but when combined with a modern immune activator - that may open up a lot of doors - crossing fingers...

-DK